Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).
Michael B AtkinsOpeyemi A JagedeNaomi B HaasDavid F McDermottMehmet A BilenMark N SteinJeffrey A SosmanRobert AlterElizabeth R PlimackMoshe C OrnsteinMichael E HurwitzDavid J PeaceSabina SignorettiThomas DenizeAlessia CimadamoreCatherine J WuDavid A BraunDavid J EinsteinPaul J CatalanoHans HammersPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Nivolumab monotherapy is active in treatment-naive ccRCC. Although efficacy appears to be less than that of nivolumab/ipilimumab in patients with intermediate-risk/poor-risk disease, favorable-risk patients had notable benefit. Efficacy correlated with tumor PD-L1 status. Salvage nivolumab/ipilimumab was frequently not feasible and of limited benefit.